Resistance | Susceptibility | Intermediate susceptibility | |
Group 1: first-line oral agents | |||
Isoniazid | 17 (100) | ||
Ethambutol | 14 (82.4) | 2 (11.8) | 1 (5.9) |
Rifampicin | 17 (100) | ||
Pyrazinamide | 9 (53) | 8 (47) | |
Rifabutin | 13 (76.5) | 3 (17.6) | 1 (5.9) |
Group 2: injectable anti-TB medication | |||
Amikacin | 7 (41.2) | 10 (58.8) | |
Kanamycin | 2 (11.8) | 4 (23.5) | |
Streptomycin | 15 (88.2) | 2 (11.8) | |
Capreomycin | 5 (29.4) | 10 (58.8) | |
Group 3: fluoroquinolones | |||
Ofloxacin | 1 (5.9) | ||
Moxifloxacin | 3 (17.6) | 13 (76.5) | 1 (5.9) |
Ciprofloxacin | 4 (23.5) | 12 (70.6) | |
Group 4: other bacteriostatic second-line agents | |||
Protionamide | 4 (23.5) | 12 (70.6) | |
Cycloserine | 1 (5.9) | 7 (41.2) | |
Group 5: anti-TB drugs with unclear efficacy | |||
Linezolid | 13 (76.5) | 3 (17.6) | |
Clofazimine | 11 (64.7) | ||
Clarithromycin | 2 (11.8) | 5 (29.4) | |
Augmentin | 9 (53) | 4 (23.5) | |
Imipenem | 2 (11.8) | ||
Others | |||
Co-trimoxazole | 4 (23.5) | 13 (76.5) | |
Ertapenem | 7 (41.2) | ||
Tigecycline | 7 (41.2) | 1 (5.9) | |
Meropenem | 1 (5.9) |
Data are presented as n (%).